Rhumbline Advisers Buys 1,879 Shares of Tyra Biosciences, Inc. $TYRA

Rhumbline Advisers boosted its stake in Tyra Biosciences, Inc. (NASDAQ:TYRA) by 7.2% during the 1st quarter, Holdings Channel.com reports. The institutional investor owned 28,081 shares of the company’s stock after buying an additional 1,879 shares during the period. Rhumbline Advisers’ holdings in Tyra Biosciences were worth $261,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of TYRA. US Bancorp DE lifted its holdings in shares of Tyra Biosciences by 50.5% during the first quarter. US Bancorp DE now owns 5,435 shares of the company’s stock valued at $51,000 after acquiring an additional 1,823 shares during the period. BNP Paribas Financial Markets acquired a new stake in shares of Tyra Biosciences during the 4th quarter worth about $60,000. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in Tyra Biosciences during the 1st quarter valued at about $84,000. Exchange Traded Concepts LLC boosted its position in Tyra Biosciences by 42.7% in the first quarter. Exchange Traded Concepts LLC now owns 11,861 shares of the company’s stock valued at $110,000 after buying an additional 3,550 shares in the last quarter. Finally, Two Sigma Advisers LP bought a new stake in Tyra Biosciences during the fourth quarter worth about $171,000. 84.14% of the stock is currently owned by institutional investors and hedge funds.

Tyra Biosciences Stock Performance

Shares of TYRA opened at $12.54 on Friday. The business’s fifty day moving average price is $11.59 and its two-hundred day moving average price is $10.36. The firm has a market capitalization of $668.38 million, a price-to-earnings ratio of -7.04 and a beta of 1.10. Tyra Biosciences, Inc. has a 52 week low of $6.42 and a 52 week high of $29.60.

Tyra Biosciences (NASDAQ:TYRA) last issued its quarterly earnings results on Thursday, August 14th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.53) by $0.06. As a group, research analysts forecast that Tyra Biosciences, Inc. will post -1.57 EPS for the current year.

Analyst Ratings Changes

A number of research analysts have recently issued reports on TYRA shares. Raymond James Financial started coverage on shares of Tyra Biosciences in a research note on Tuesday, September 2nd. They issued a “strong-buy” rating and a $35.00 target price for the company. HC Wainwright reissued a “buy” rating and issued a $30.00 price objective on shares of Tyra Biosciences in a research note on Friday, August 22nd. Oppenheimer restated an “outperform” rating and set a $36.00 target price on shares of Tyra Biosciences in a report on Wednesday, September 10th. Finally, Wall Street Zen raised Tyra Biosciences from a “sell” rating to a “hold” rating in a report on Saturday, September 13th. One analyst has rated the stock with a Strong Buy rating and six have given a Buy rating to the stock. According to MarketBeat, Tyra Biosciences currently has an average rating of “Buy” and an average price target of $31.86.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.